Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epithelial ovarian, fallopian tube, or primary peritoneal cancer confirmed by pathology (biopsy/pathology report).
- Your cancer progressed during or within 6 months after at least one platinum chemotherapy regimen (including if it progressed while you were on it).
- You have limited prior treatments in this “platinum-resistant” situation (no more than 4) and no more than 7 total in all settings; maintenance targeted/bio medicines don’t count as extra treatment lines.
- There is at least one measurable tumor spot on scans that can be followed over time.
- Your body is strong enough for treatment: performance status 0–1, blood counts (ANC, platelets, hemoglobin) meet minimums, and kidney and liver tests are within allowed ranges.
- For the ONC201 PK/PD part, you must have available tumor tissue from a prior biopsy, or agree to get a new biopsy before starting study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new liquid form of paclitaxel (a common chemotherapy drug) in women whose ovarian, fallopian tube, or primary peritoneal cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this new formulation is safe and effective for this difficult-to-treat situation.
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Hear when a new Platinum-Resistant Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.